Developed and implemented consumer marketing materials for NUCALA, an anti-IL5 biologic, at GSK

Handled the development, approval and production of marketing materials for cardiovascular and mature brands at a large multinational pharmaceutical company

Fostered and facilitated healthcare professional marketing for resmetirom, a thyroid hormone receptor beta-selective agonist in development for nonalcoholic steatohepatitis (NASH). Led and managed launch preparation activities to include disease-state education, advertising campaign, conference activities and peer-to-peer education programs.

Facilitated healthcare professional marketing for tebipenem, an oral carbapenem antibiotic. Led and managed launch preparation activities to include brand development, packaging creative, disease-state education, advertising campaign and peer-to-peer educations programs.• Drove development of branding for tebipenem including name, logo, brand persona and packaging• Launched disease-state education campaign to raise HCP awareness of the company and the need for new oral antibiotics• Developed branded messages and the creative advertising campaign for launch• Supervised one direct report responsible for the development and management of promotional speaker programs

Led healthcare professional marketing and launch preparation activities for NUZYRA, a tetracycline-derivative antibiotic, in both hospital and community settings.• Led development of the hospital advertising campaign, messaging and infectious disease HCP marketing materials• Headed a cross-functional team to initiate pilot program for promotion of NUZYRA to primary care physicians• Generated deep customer insights on launch materials, speaker programs and infusion center strategies through advisory boards conducted with thought leaders and key customers• Increased physician awareness of NUZYRA through multi-channel marketing programs including improvement of salesforce materials and non-personal promotion

Utilized marketing and pharmaceutical experience to make brands and companies more successful.• Handled the development, approval and production of managed care pull-through materials for an opioid-induced constipation brand at a large multinational pharmaceutical company• Created and managed corporate website and social media for a start-up pharmaceutical company

Managed overall strategy, execution and measurement of men’s health portfolio consumer marketing programs. Key brands included EDEX, STENDRA, TESTIM, TESTOPEL and XIAFLEX. Implemented digital marketing assets including websites, paid search, display banner ads, digital videos and online sponsorships. Oversaw and managed a $17 MM budget.• Led development of award winning XIAFLEX consumer campaign for Dupuytren’s Contracture• Created customer relationship marketing program with multiple email touchpoints designed to educate consumers, drive consumers to their doctor and foster conversion• Guided media strategy, purchase and measurement across portfolio

Handled strategy, execution and measurement of CRESTOR consumer marketing programs with emphasis in relationship marketing, co-pay savings card programs and digital.• Oversaw opt-in database direct marketing activities including conversion, loyalty and re-contact programs. Program increased adherence by 13% with an ROI of 1.7 to 1• Developed and implemented co-pay savings card, free trial certificate and pharmacy tear-pad programs designed to address consumer cost concerns. Programs resulted in over 848,000 annual redemptions with $35 Million worth of claims with an ROI of 2.3 to 1• Implemented consumer digital marketing tactics including web-site design, web portal partnerships, search engine optimization and digital media• Developed and implemented pharmacy-based acquisition and loyalty/refill-reminder programs with ROIs up to 2.7 to 1

Developed and implemented innovative adherence practices with consumers, healthcare professionals, managed care organizations and pharmacy customers.

Led a cross-functional team to provide global commercial input for the decision to enter phase 3 clinical trials for BRILINTA, an oral anti-platelet in development for arterial thrombosis.

Delivered strategic insight for commercial assessments of products in early phases of development in dyslipidemia, atrial fibrillation and type 2 diabetes.

Conducted market research to support US commercial input for pre-launch products and in-licensing candidates in oncology, cardiovascular, asthma and multiple sclerosis.